EA200900804A1 - MEANS ACTIVATING SEXUAL FUNCTION - Google Patents
MEANS ACTIVATING SEXUAL FUNCTIONInfo
- Publication number
- EA200900804A1 EA200900804A1 EA200900804A EA200900804A EA200900804A1 EA 200900804 A1 EA200900804 A1 EA 200900804A1 EA 200900804 A EA200900804 A EA 200900804A EA 200900804 A EA200900804 A EA 200900804A EA 200900804 A1 EA200900804 A1 EA 200900804A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- sexual function
- heptapeptide
- pro
- rat
- noted
- Prior art date
Links
Abstract
Изобретение относится к гептапептиду (Thr-Lyz-Pro-Arg-Pro-Gly-Pro), применяемому в качестве средства, активирующего половую функцию. Показано в опытах на крысах самцах, что однократная (100 мкг/крысу) или трехкратная (3 раза по 100 мкг/крысу) инъекция гептапептида вызывала активацию центральных пусковых механизмов половой функции, что проявлялось значительным (более чем 3-кратным) сокращением времени латентности садок и интромиссий. Общее структурное усиление половой функции отмечали на 7-й день после последней инъекции гептапептида (отсроченный эффект). Увеличивалось также число эякуляций при сокращении ее временных характеристик. Препарат сравнения (экстракт горца птичьего) проявлял более слабую стимулирующую половую функцию активность и не проявлял эффекта последействия, отмеченного для гептапептида.The invention relates to heptapeptide (Thr-Lyz-Pro-Arg-Pro-Gly-Pro), used as a means of activating sexual function. It was shown in experiments on male rats that a single (100 μg / rat) or three times (3 times 100 μg / rat) heptapeptide injection caused the activation of the central triggers of sexual function, which was manifested by a significant (more than 3-fold) reduction of the cage and intromissy. General structural enhancement of sexual function was noted on the 7th day after the last injection of heptapeptide (delayed effect). The number of ejaculations also increased while reducing its temporal characteristics. The comparator drug (poultry mountaineer extract) showed a weaker stimulatory sexual function and did not show the effect of the aftereffect noted for heptapeptide.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA200900804A EA200900804A1 (en) | 2009-06-08 | 2009-06-08 | MEANS ACTIVATING SEXUAL FUNCTION |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA200900804A EA200900804A1 (en) | 2009-06-08 | 2009-06-08 | MEANS ACTIVATING SEXUAL FUNCTION |
Publications (2)
Publication Number | Publication Date |
---|---|
EA013948B1 EA013948B1 (en) | 2010-08-30 |
EA200900804A1 true EA200900804A1 (en) | 2010-08-30 |
Family
ID=42779161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200900804A EA200900804A1 (en) | 2009-06-08 | 2009-06-08 | MEANS ACTIVATING SEXUAL FUNCTION |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA200900804A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2507212C2 (en) * | 2012-03-28 | 2014-02-20 | Общество С Ограниченной Ответственностью "Айвикс" | Method of producing recombinant peptide and obtained peptide |
US10836794B2 (en) | 2016-10-24 | 2020-11-17 | “Ivix” Ltd. | Group of peptides for treating female sexual dysfunction |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2404793C1 (en) | 2009-06-04 | 2010-11-27 | Общество с ограниченной ответственностью Био Пептид | Stimulator of genital, sexual and reproductive function |
RU2655763C2 (en) * | 2016-10-24 | 2018-05-29 | Общество С Ограниченной Ответственностью "Айвикс" | Pharmaceutical composition and method for treating female sexual dysfunctions |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2155065C1 (en) * | 1999-04-23 | 2000-08-27 | Институт молекулярной генетики РАН | Anxiolytic agent and pharmaceutical composition with anxiolytic effect |
-
2009
- 2009-06-08 EA EA200900804A patent/EA200900804A1/en not_active IP Right Cessation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2507212C2 (en) * | 2012-03-28 | 2014-02-20 | Общество С Ограниченной Ответственностью "Айвикс" | Method of producing recombinant peptide and obtained peptide |
US9409947B2 (en) | 2012-03-28 | 2016-08-09 | “Ivix” Ltd. | Method for producing a recombinant peptide and resultant peptide |
US10836794B2 (en) | 2016-10-24 | 2020-11-17 | “Ivix” Ltd. | Group of peptides for treating female sexual dysfunction |
Also Published As
Publication number | Publication date |
---|---|
EA013948B1 (en) | 2010-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018260800B2 (en) | Hepcidin analogues and uses therof | |
WO2012177444A3 (en) | Glucagon/glp-1 receptor co-agonists | |
WO2012177443A3 (en) | Glucagon/glp-1 receptor co-agonists | |
MX2013010376A (en) | Stable formulations for parenteral injection of peptide drugs. | |
CR20130667A (en) | COMPOSITIONS CONTAINING, METHODS THAT INVOLVED, AND USES DERIVED FROM DOLASTATIN UNITED TO NON-NATURAL AMINO ACIDS | |
MX2007009162A (en) | Alcohol resistant dosage forms. | |
MX367850B (en) | PREVENTION and TREATMENT OF INFLAMMATORY CONDITIONS. | |
UA103025C2 (en) | Solid pharmaceutical formulation with delayed release | |
EA200900804A1 (en) | MEANS ACTIVATING SEXUAL FUNCTION | |
MY172040A (en) | Synergistic dietary supplement for enhancing physical performance | |
GB2497453A (en) | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV | |
PH12015502100A1 (en) | Reducing the risk of autoimmune disease | |
PH12015502072B1 (en) | Nutritional compositions containing a peptide component and uses thereof | |
WO2011156811A3 (en) | Compounds for treatment of bovine mastitis | |
MX338405B (en) | 2-iminobiotin formulations and uses thereof. | |
UA105552C2 (en) | Plant extract for treating neurodegenerative diseases | |
WO2016149382A3 (en) | Compositions and methods for suppressing or reducing systemic immune response in a subject | |
EA201492238A1 (en) | COMPOSITION MIZOPROSTOL | |
WO2014006571A3 (en) | Extended-release pharmaceutical dosage forms of carbidopa and levodopa and processes of preparation thereof | |
UA108865C2 (en) | PARENTERAL PHARMACEUTICAL COMPOSITION IN THE VIEW OF THE SUSPENSION OF SUSTAINED RELEASE | |
WO2011133897A3 (en) | Methods and materials for reducing liver fibrosis | |
HUP1600040A2 (en) | Process for permanent aromatizing and increasing the nashing efficiency of soap nuts' shell, and compositions based on soap nut shell prepared by the process itself | |
WO2013117789A3 (en) | Formylated xanthocillin analogues as neuroprotectants | |
EA201992040A1 (en) | PERINATAL ADMINISTRATION OF SHORT-CHAIN FRUIT-LIGOSACCHARIDES FOR PREVENTION OF METABOLIC DISORDERS RELATED TO UNBALANCED NUTRITION AS AN ADULT | |
IN2013DE03119A (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ KG MD TJ TM |
|
PC4A | Registration of transfer of a eurasian patent by assignment |